Lapatinib – a HER-(1+02 inhibitor and a small molecule compared with herceptin has some activity in HER-2 positive breast cancer patients with brain metastases; this type of advance may have further usefulness in the future. This evidence concerns the gene ERBB2 and breast carcinoma.